Welcome to our dedicated page for Serina Therapeutics news (Ticker: ser), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Serina Therapeutics Inc (SER) is a clinical-stage biotechnology innovator advancing neurological and pain therapies through its proprietary POZ Platform technology. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry observers will find timely updates on clinical trial progress, regulatory developments, and strategic partnerships. Our curated collection includes press releases on drug candidate advancements, peer-reviewed research findings, and executive commentary – all essential for understanding SER's position in biopharmaceutical innovation.
Key focus areas include updates on the POZ Platform's application in drug delivery systems, trial phase transitions, and collaborative research initiatives. Content is organized to provide clear context about how each development aligns with the company's mission to improve neurological and pain management therapies.
Bookmark this page for direct access to primary source materials from Serina Therapeutics. Check regularly for new insights into the company's scientific advancements and operational milestones in the competitive biotech landscape.
Serina Therapeutics (NYSE American: SER) has announced the sale of its UniverXome subsidiary, completed on December 23, 2024. The transaction eliminates $11.2 million in subsidiary-level debt, resulting in a debt-free balance sheet for Serina entering 2025.
The UniverXome subsidiary was established before Serina's reverse merger with AgeX Therapeutics in March 2024 to hold legacy assets. This strategic move aligns with Serina's focus on advancing SER-252, their lead candidate for advanced Parkinson's disease, into clinical development. The company aims to explore their POZ Platform™ technology across multiple therapeutic applications, including small molecules, lipid nanoparticles (LNPs), and antibody-drug conjugates (ADCs).
Serina Therapeutics (NYSE American: SER) has announced the appointment of Karen J. Wilson to its Board of Directors. Wilson brings over 30 years of leadership experience in life sciences, currently serving on the boards of Connect Biopharma Holdings, Elicio Therapeutics, and LAVA Therapeutics.
Wilson previously held senior finance positions at Jazz Pharmaceuticals, including Senior Vice President of Finance and Principal Accounting Officer. Her prior experience includes senior finance roles at PDL BioPharma, ViroLogic, and Novare Surgical Systems, as well as consulting and auditing at Deloitte & Touche LLP. She is a Certified Public Accountant with a B.S. in Business from UC Berkeley.
The company also announced the departure of Steven Mintz from its Board of Directors, who helped guide Serina's transition from private to public company.
Serina Therapeutics (NYSE: SER) has announced a upcoming webinar presentation focused on continuous drug delivery solutions for Parkinson's disease. The event, titled 'Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond,' will feature CEO Steven A. Ledger and is scheduled for December 18, 2024, at 8:30 AM Pacific/11:30 AM Eastern.
The presentation will address continuous dopaminergic stimulation (CDS), which has demonstrated effectiveness in reducing motor complications in advanced Parkinson's patients. The discussion will compare Serina's IND candidate's target product profile with current standard treatments in providing CDS. The event will be hosted by Tribe Public's Managing Member John F. Heerdink, Jr., and will include a Q&A session.
Serina Therapeutics (NYSE American: SER) announced that their Chief Development Officer, Randall Moreadith, MD, PhD, will present at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston. The presentation focuses on their proprietary POZ-lipid technology, which shows promising results in improving lipid nanoparticle (LNP) formulations.
Key findings demonstrate that POZ-lipid did not trigger IgM or IgG antibody responses after repeated administration in animal testing. This contrasts with conventional PEG-lipids, which produced strong antibody responses. The absence of immune response to POZ-lipid suggests potential for developing safer LNP formulations, particularly significant given that anti-PEG antibody responses have been linked to hypersensitivity reactions in mRNA-based vaccine recipients.
Serina Therapeutics (NYSE American: SER) has secured a $10 million equity financing from JuvVentures (UK) to advance SER-252 (POZ-apomorphine) into Phase 1 clinical trials for advanced Parkinson's disease patients in H2 2025. The financing involves issuing one million shares at $10 per share, representing a 120% premium to the November 26 closing price. The funding will be delivered in two $5 million tranches, with the first received on November 27, 2024, and the second due by January 31, 2025.
Serina Therapeutics (NYSE American: SER) reported Q3 2024 financial results and business updates. The company's revenue was $14,000 from NIH grants, down from $29,000 in Q3 2023. Operating expenses increased to $5.3 million from $1.5 million year-over-year. Despite reporting net income of $1.4 million ($0.16 per basic share), the company faces substantial going concern issues with only $3.2 million in cash as of September 30, 2024. Key highlights include a partnership with Enable Injections for their lead candidate SER-252, targeting advanced Parkinson's disease through their POZ Platform™ technology.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to three new non-executive employees. The grants, totaling 60,500 shares of common stock, were made on November 6, 2024, with exercise prices matching the closing stock price on that date. These options were approved as employment inducement awards under NYSE American's Company Guide Section 711(a). The options will vest over three years, with one-third vesting after the first year and the remaining two-thirds vesting in 24 monthly installments, contingent on continued employment.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company, announced its participation in the 14th Annual Injectables Summit in Boston, MA. The company's Chief Development Officer, Randall Moreadith, MD, PhD, will present alongside Enable Injections' Chief Commercial Officer Matthew Huddleston.
Their joint presentation, titled 'Patient-enabled Therapy for Advanced Parkinson's Disease', will focus on the collaboration between Serina's SER-252 and Enable Injections' enFuse Wearable Drug Delivery Platform. This partnership aims to provide advanced Parkinson's Disease patients with life-changing therapeutics through comfortable and convenient delivery methods.
Serina Therapeutics is known for developing its proprietary POZ Platform™ drug delivery technology, which is likely to be a key component in this collaborative effort to improve patient care and treatment outcomes.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Steve Ledger, Serina's Interim CEO, will present on September 11, 2024, at 12:00 p.m. ET.
Serina is known for developing its proprietary POZ Platform™ drug delivery technology. Investors and interested parties can access a live webcast of the presentation through the Investor section of Serina's website. An archived replay will also be available for a time after the event.
This presentation offers an opportunity for Serina to showcase its innovative technology and progress to a global investment audience, potentially impacting its stock performance and investor interest.
Serina Therapeutics (NYSE American: SER) reported Q2 2024 financial results and business highlights. Key points include:
1. Partnership with Enable Injections for SER-252 development in Parkinson's disease
2. Presentation of POZ-lipid immunogenicity data showing potential safety improvements for mRNA-LNP formulations
3. Appointment of Dr. Srini Tenjarla as SVP of CMC & Formulation
Financial highlights:
- Cash and equivalents: $6.1 million as of June 30, 2024
- Q2 2024 revenues: $51,000 (vs $7,000 in Q2 2023)
- Q2 2024 operating expenses: $3.9 million (vs $1 million in Q2 2023)
- Q2 2024 net income: $5.2 million or $0.61 per share (basic)
The company faces going concern considerations due to projected cash flows.
FAQ
What is the current stock price of Serina Therapeutics (ser)?
What is the market cap of Serina Therapeutics (ser)?
